天然活性成分治疗肺动脉高压的研究进展

doi:10.16352/j.issn.1001-6325.2026.08.1130

基础医学与临床 ›› 2026, Vol. 46 ›› Issue (8): 1130-1134.doi: 10.16352/j.issn.1001-6325.2026.08.1130

天然活性成分治疗肺动脉高压的研究进展

杨春艳¹, 张佳玮², 邢岩江², 李斌¹, 刘海涛^1*

1.中国医学科学院北京协和医学院药用植物研究所天然药物活性物质与功能国家重点实验室,北京 100193;
2.中国医学科学院北京协和医学院基础医学研究所呼吸和共病全国重点实验室,北京 100005

收稿日期:2026-04-03 修回日期:2026-05-26 发布日期:2026-07-22
通讯作者: ^*htliu@implad.ac.cn
基金资助:
国家自然科学基金(U23A20511);中国医学科学院医学与健康科技创新工程(2024-I2M-TS-019);北京市自然科学基金(Z220019)

Research progress on natural bioactive components in the treatment of pulmonary arterial hypertension

YANG Chunyan¹, ZHANG Jiawei², XING Yanjiang², LI Bin¹, LIU Haitao^1*

1. State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193;
2. State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing100005, China

Received:2026-04-03 Revised:2026-05-26 Published:2026-07-22
Contact: ^*htliu@implad.ac.cn

摘要/Abstract

摘要： 肺动脉高压(PAH)以肺血管重塑为核心特征,现有治疗难以逆转。天然活性成分凭借多靶点优势为PAH干预提供新策略。本文系统梳理了天然活性成分抗PAH的机制特征,涵盖改善血管舒缩、抑制平滑肌增殖、调节炎性反应及代谢重编程等多维网络作用;深度剖析了当前研究在直接分子靶点验证、模型与结构性终点评价及成药性等方面的证据局限;并提出加强靶点确证、升级临床前评价体系及优化递送系统的转化思考,以期为推动天然活性成分在PAH中的实质性临床转化提供参考。

关键词: 肺动脉高压, 天然活性成分, 转化医学

Abstract: Pulmonary arterial hypertension(PAH) is characterized by pulmonary vascular remodeling, which is difficult to reverse with current therapies. Natural bioactive components provide a novel strategy for PAH intervention due to their multi-target advantages. This review systematically summarizes the mechanistic characteristics of natural bioactive components against PAH, encompassing multi-dimensional network effects such as improving vasomotor function, inhibiting smooth muscle cell proliferation, modulating inflammatory responses, and correcting metabolic reprogramming. Furthermore, it profoundly analyzes the evidence limitations in current research regarding direct molecular target validation, experimental models, structural endpoint evaluation, and druggability. Finally, we provide translational perspectives on strengthening target validation, upgrading pre-clinical evaluation systems, and optimizing delivery systems, aiming to provide a reference for promoting the substantive clinical translation of natural bioactive components in PAH.

Key words: pulmonary arterial hypertension, natural bioactive components, translational medicine

中图分类号:

R285.5
R543

杨春艳, 张佳玮, 邢岩江, 李斌, 刘海涛. 天然活性成分治疗肺动脉高压的研究进展[J]. 基础医学与临床, 2026, 46(8): 1130-1134.

YANG Chunyan, ZHANG Jiawei, XING Yanjiang, LI Bin, LIU Haitao. Research progress on natural bioactive components in the treatment of pulmonary arterial hypertension[J]. Basic & Clinical Medicine, 2026, 46(8): 1130-1134.

参考文献

[1] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61: 2200879. doi:10.1183/13993003.00879-2022.
[2] Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10: 1. doi:10.1038/s41572-023-00486-7.
[3] Maron BA. Sotatercept and the clinical transformation of pulmonary arterial hypertension[J]. N Engl J Med, 2025, 392: 2059-2061.
[4] Yang X, Yang Y, Liu K, et al. Traditional Chinese medicine monomers: Targeting pulmonary artery smooth muscle cells proliferation to treat pulmonary hypertension[J]. Heliyon, 2023, 9: e14916. doi:10.1016/j.heliyon.2023.e14916.
[5] Wang X, Deng T, Zhu H, et al. Chinese herbal medicine in hypoxic pulmonary hypertension treatment: mechanisms, progress, and future directions[J]. Drug Des Devel Ther, 2025, 19: 8265-8294.
[6] Cuthbertson I, Morrell NW, Caruso P. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension[J]. Circ Res, 2023, 132: 109-126.
[7] Zhang JR, Ouyang X, Hou C, et al. Natural ingredients from Chinese materia medica for pulmonary hypertension[J]. Chin J Nat Med, 2021, 19: 801-814.
[8] Sun ZY, Lu GQ, Sun HY, et al. Salidroside amelio-rates hypoxic pulmonary hypertension by regulating the two-pore domain potassium TASK-1 channel[J]. Phytomedicine, 2024, 135: 156206. doi:10.1016/j.phymed.2024.156206.
[9] Li J, Zhang Z, Zhu C, et al. Salidroside enhances NO bioavailability and modulates arginine metabolism to alleviate pulmonary arterial hypertension[J]. Eur J Med Res, 2024, 29: 423. doi:10.1186/s40001-024-02016-x.
[10] Provencher S, Archer SL, Ramirez FD, et al. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research[J]. Circ Res, 2018, 122: 1021-1032.
[11] Niu Z, Fu M, Li Y, et al. Osthole alleviates pulmonary vascular remodeling by modulating microRNA-22-3p mediated lipid metabolic reprogramming[J]. Phytomedicine, 2022, 96: 153840. doi:10.1016/j.phymed.2021.153840.
[12] Tang BL, Liu Y, Zhang JL, et al. Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1[J]. Biomed Pharmacother, 2023, 164: 114920. doi:10.1016/j.biopha.2023.114920.
[13] Li M, Ying M, Gu S, et al. Matrine alleviates hypoxia-induced inflammation and pulmonary vascular remodelling via RPS5/NF-κB signalling pathway[J]. J Biochem Mol Toxicol, 2024, 38: e23583. doi:10.1002/jbt.23583.
[14] Lei W, Chen MH, Huang ZF, et al. Salidroside protects pulmonary artery endothelial cells against hypoxia-induced apoptosis via the AhR/NF-κB and Nrf2/HO-1 pathways[J]. Phytomedicine, 2024, 128: 155376. doi:10.1016/j.phymed.2024.155376.
[15] Li W, Chen W, Peng H, et al. Shikonin improves pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension via regulation of PKM2[J]. Mol Med Rep, 2023, 27: 60. doi:10.3892/mmr.2023.12947.
[16] Xi J, Ma Y, Liu D, et al. Astragaloside Ⅳ restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway[J]. BMC Pulm Med, 2023, 23: 386. doi:10.1186/s12890-023-02660-9.
[17] Tabana Y, Babu D, Fahlman R, et al. Target identifica-tion of small molecules: an overview of the current applications in drug discovery[J]. BMC Biotechnol, 2023, 23: 44. doi:10.1186/s12896-023-00815-4.
[18] Boucherat O, Agrawal V, Lawrie A, et al. The latest in animal models of pulmonary hypertension and right ventricular failure[J]. Circ Res, 2022, 130: 1466-1486.
[19] Lemay SE, Montesinos MS, Grobs Y, et al. Exploring integrin α5β1 as a potential therapeutic target for pulmonary arterial hypertension: insights from comprehensive multicenter preclinical studies[J]. Circulation, 2025, 151: 1162-1183.
[20] Asano T. Investigating the pharmacokinetics of natural products: Challenges and advances in bioavailability[J]. J Pharmacogn Nat Prod, 2024, 10: 326.
[21] Yang DP, Dong WP, Yang YC, et al. Tetramethylpyra-zine improves monocrotaline-induced pulmonary hypertension through the ROS/iNOS/PKG-1 axis[J]. J Healthc Eng, 2022, 2022: 1890892. doi:10.1155/2022/1890892.
[22] Chen Y, Lu W, Yang K, et al. Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension[J]. Br J Pharmacol, 2020, 177: 2743-2764.
[23] Balkrishna A, Sharma N, Srivastava D, et al. Exploring the safety, efficacy, and bioactivity of herbal medicines: bridging traditional wisdom and modern science in healthcare[J]. Future Integr Med, 2024, 3: 35-49.
[24] Jyothi MV, Vl AB, Wagh VD, et al. Herbal interactions with cardiac medications: a comprehensive review of potential interactions between herbal drugs and commonly prescribed cardiac medications[J]. Curr Drug Saf, 2025, 20: 94-119.
[25] Park JS, Choi YH, Min JY, et al. Fundamental and targeted approaches in pulmonary arterial hypertension treatment[J]. Pharmaceutics, 2025, 17: 224. doi:10.3390/pharmaceutics17020224.

天然活性成分治疗肺动脉高压的研究进展

Research progress on natural bioactive components in the treatment of pulmonary arterial hypertension

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘祺为, 李霓, 张皓冰, 张红, 宋婉璐, 胡宇飞, 杨沛然. 紫杉叶素通过调节白细胞趋化性和Ackr受体减轻野百合碱诱导的实验性动脉型肺动脉高压[J]. 基础医学与临床, 2026, 46(8): 1082-1089.
[2]	段文鑫, 宋婉璐, 杨沛然, 王婧. 慢性血栓栓塞性肺动脉高压组学研究进展[J]. 基础医学与临床, 2025, 45(7): 963-968.
[3]	陆晓萱, 郭丽娜, 张红, 宋婉璐, 胡宇飞, 杨沛然. 内皮细胞增殖及细胞外基质相关通路调控模型大鼠动脉性肺动脉高压[J]. 基础医学与临床, 2025, 45(6): 770-776.
[4]	张宗丽, 李涛, 马菁文, 张嘉鑫, 李兴朝, 席世兵. 氧浓度变化对人肺动脉内皮细胞中ANGPTL8表达的影响[J]. 基础医学与临床, 2025, 45(1): 12-19.
[5]	胡崧, 华潞, 张健. 肺动脉高压的抗凝治疗:必要性与困境[J]. 基础医学与临床, 2024, 44(8): 1062-1067.
[6]	邓渊瑞, 王晓建. 肺动脉高压代谢组学:从病理机制到治疗靶点[J]. 基础医学与临床, 2024, 44(8): 1074-1079.
[7]	钱喜锋, 华潞. 炎性细胞与动脉性肺动脉高压血管重塑[J]. 基础医学与临床, 2024, 44(8): 1080-1087.
[8]	高艺丹, 蒋雪涵, 张红, 杨沛然. 靶向异常通路的动脉性肺动脉高压新型药物研发[J]. 基础医学与临床, 2024, 44(8): 1088-1093.
[9]	付志刚, 覃佳, 谭江山. 门脉高压性肺动脉高压:诊治进展与挑战[J]. 基础医学与临床, 2024, 44(8): 1068-1073.
[10]	刘幸幸, 王威威, 袁好鑫. 内质网应激在低氧性肺动脉高压中作用的研究进展[J]. 基础医学与临床, 2023, 43(5): 848-851.
[11]	李发美, 余再新. 神经酰胺的功能及其在肺动脉高压中的作用[J]. 基础医学与临床, 2021, 41(2): 267-271.
[12]	李玥, 魏怡真, 张丁丁, 朱惠娟, 刘继海, 罗林枝, 张抒扬. 导师培训项目提升临床和转化医学导师的自信心和技能[J]. 基础医学与临床, 2020, 40(6): 856-862.
[13]	邢书娟, 董明清, 杨力侠, 罗颖. 两种肺动脉高压模型小鼠的基因表达谱分析[J]. 基础医学与临床, 2020, 40(11): 1462-1467.
[14]	庞海玉徐锡霞吴志宏张抒扬. 医院科研统计咨询工作实践与技能调查[J]. 基础医学与临床, 2018, 38(12): 1808-1812.
[15]	王海燕王刚张晓岩李菊英贺菊香李生花. 二十味沉香丸增强低氧性肺动脉高压大鼠肺组织PKC-α表达[J]. 基础医学与临床, 2014, 34(6): 844-846.